GEN Exclusives

More »

GEN News Highlights

More »
Mar 7, 2007

Stemline Therapeutics In-Licenses Oncology Compound

  • Stemline Therapeutics in-licensed the exclusive worldwide rights to SL-401, a Phase I compound directed at a cancer stem cell target from the Scott & White Cancer Research Institute/Texas A&M Health Science Center College of Medicine. SL-401 has reportedly demonstrated single agent antitumor activity in a multicenter, dose-escalation study.

    SL-401 targets the interleukin-3 receptor (IL-3R) and has been shown to impair the ability of cancer stem cells to form tumors.  IL-3R is over-expressed on multiple hematological cancers. In AML, IL-3R is over-expressed on both leukemia blasts as well as leukemia cancer stem cells.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?